Literature DB >> 6378807

Comparison of three different methods of monitoring unwanted effects during antihypertensive therapy.

C Borghi, G Pallavini, D Comi, G Grillo, M Lombardo, O Mantero, L Minetti, A Selvini, G Suppa.   

Abstract

In a double-blind, randomized, crossover, multicenter study performed in 227 hypertensive outpatients, two antihypertensive drugs, oxprenolol and chlorthalidone, were investigated to determine unwanted effects. Three main methodologic procedures were applied: the conventional evaluation of unwanted effects by the physician and involving the whole patient population, the checklist, and the free questionnaire. The latter two were assigned by randomization to the patients themselves. The study showed that unwanted effects seem to be frequently overreported when a checklist is used, whereas the free questionnaire gives more information about the symptoms of the disease than about the tolerance of the drug. The conventional method, when physicians are well-informed and sensitized to the problem, seems to provide more reliable information about unwanted effects of a drug.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6378807

Source DB:  PubMed          Journal:  Int J Clin Pharmacol Ther Toxicol        ISSN: 0174-4879


  4 in total

1.  Evaluation of three methods of symptom reporting in a clinical trial of felodipine.

Authors:  M A Wallander; E Dimenäs; K Svärdsudd; I Wiklund
Journal:  Eur J Clin Pharmacol       Date:  1991       Impact factor: 2.953

Review 2.  The way towards adverse event monitoring in clinical trials.

Authors:  M A Wallander
Journal:  Drug Saf       Date:  1993-03       Impact factor: 5.606

3.  Intraindividual comparison of moxonidine and prazosin in hypertensive patients.

Authors:  V Plänitz
Journal:  Eur J Clin Pharmacol       Date:  1986       Impact factor: 2.953

Review 4.  Eliciting adverse effects data from participants in clinical trials.

Authors:  Elizabeth N Allen; Clare Ir Chandler; Nyaradzo Mandimika; Cordelia Leisegang; Karen Barnes
Journal:  Cochrane Database Syst Rev       Date:  2018-01-16
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.